Our analysis revealed a significant reduction in global methylation levels in the MAPT promoter region and SNCA intron 1 in PD patients compared to controls (MAPT, p = 0.0019; SNCA, p = 0.000069). The gene discussed is MAPT; the disease is Parkinson disease.